Intellia Therapeutics, Inc.
Congressional Trades
Whale Activity
- Increased116
- New30
- Held60
- Decreased91
- Closed47
- No prior filing15
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 16.0M | $193.4M | increased |
| ARK Investment Management LLC | 15.9M | $192.1M | decreased |
| STATE STREET CORP | 7.8M | $94.2M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.4M | $89.1M | increased |
| D. E. Shaw & Co., Inc. | 6.1M | $73.1M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $72.9M | increased |
| TWO SIGMA INVESTMENTS, LP | 4.7M | $56.8M | decreased |
| FMR LLC | 4.7M | $56.6M | decreased |
| REGENERON PHARMACEUTICALS, INC. | 3.7M | $44.7M | held |
| Amova Asset Management Americas, Inc. | 3.6M | $43.5M | increased |
| Sumitomo Mitsui Trust Group, Inc. | 3.6M | $43.5M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.5M | $42.1M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| LEONARD JOHN MPresident and CEO · Director | Sale | −9,000 | $11.99 | $108K | Nov 2, 2026 | Form 4 ↗ |
| Dube Michael PVP, Chief Accounting Officer | Sale | −1,864 | $12.43 | $23K | Oct 2, 2026 | Form 4 ↗ |
| LEONARD JOHN MPresident and CEO · Director | Sale | −2,785 | $13.00 | $36K | Aug 21, 2026 | Form 4 ↗ |
| LEONARD JOHN MPresident and CEO · Director | Sale | −19.9K | $12.60 | $251K | Aug 20, 2026 | Form 4 ↗ |
| Dulac Edward J IIIEVP, Chief Financial Officer | Sale | −8,111 | $11.25 | $91K | Jul 22, 2026 | Form 4 ↗ |
| Dulac Edward J IIIEVP, Chief Financial Officer | Sale | −4,677 | $18.00 | $84K | Jul 2, 2026 | Form 4 ↗ |
| Dube Michael PVP, Chief Accounting Officer | Sale | −2,641 | $16.78 | $44K | Jul 1, 2026 | Form 4 ↗ |
| GOODMAN JESSEDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| CHASE WILLIAM JDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Verwiel FrankDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Keresty GeorgiaDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Goff BrianDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Cohen Fred EDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Bhanji MunaDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| BASTA JAMESEVP, General Counsel | Sale | −1,211 | $13.78 | $17K | Mar 2, 2026 | Form 4 ↗ |
| Clark ElianaEVP, Chief Technical Officer | Sale | −607 | $13.78 | $8K | Mar 2, 2026 | Form 4 ↗ |
| LEONARD JOHN MPresident and CEO · Director | Grant / award | +156.4K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| BASTA JAMESEVP, General Counsel | Grant / award | +46.1K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| Lebwohl DavidEVP, Chief Medical Officer | Grant / award | +9,943 | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| Dulac Edward J IIIEVP, Chief Financial Officer | Grant / award | +61.3K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| ARK Innovation ETF ARK ETF Trust | 10.0M | $106.7M | 1.92% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 5.8M | $97.4M | 0.91% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.3M | $72.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.5M | $59.6M | 0.07% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.1M | $52.6M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $30.4M | 0.06% | Jun 30, 2026 |
| ARK Genomic Revolution ETF ARK ETF Trust | 2.7M | $28.5M | 1.83% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $27.2M | 0.03% | Jun 30, 2026 |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 1.9M | $24.4M | 0.39% | Aug 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 1.3M | $21.4M | 0.15% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list NTLA's shares (CUSIP 45826J105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.8M shares5.6%
Nov 10, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 9.2M shares6.8%
Aug 7, 2026 · ↗ - GOLDMAN SACHS & CO. LLCSCHEDULE 13G · passive (13G) · 5.5M shares5.1%
Nov 12, 2025 · ↗ - THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G · passive (13G) · 5.5M shares5.1%
Nov 12, 2025 · ↗
Corporate Lobbying
No lobbying filings found naming Intellia Therapeutics, Inc. as the client.
- CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2022 Q1—
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2022 Q1—
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q4 · HCR$30K
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q3 · HCR$30K
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q2 · HCR$30K
Filing ↗
Government Contracts
No federal contract awards found for Intellia Therapeutics, Inc..
U.S. Patents
No USPTO patent applications found for Intellia Therapeutics, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M |
| Diluted EPS | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.78 |
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M |
| Cash and equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M |
| Total assets | $842.1M | $1.19B | $1.30B | $1.52B | $1.29B |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | n/a |
| Shareholders' equity | $671.4M | $872.0M | $1.05B | $1.24B | $1.04B |
As Intellia Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
No stock splits in NTLA's price history.
Material Events (8-K)
- 8-K/A · Items 7.01, 9.01Reg FD disclosureNov 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 7.01, 9.01Material agreement · Direct financial obligation · Reg FD disclosureSep 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗



